Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.79M$4.79Mderived+72.2% vs Q4 2021 Net Income-$4.79M-$4.79MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,509,337−9.9% Operating Incomederived-$4,770,650N/M Operating Cash Flowderived-$3,215,992N/M Free Cash Flowderived-$3,273,270N/M Margins · derivedGross margin31.5%−28.7 pt vs Q4 2021
Operating margin-99.6%+107.2 pt vs Q4 2021
Net margin-100.0%+111.2 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end